CVIR Endovascular最新文献

{"title":"Photon counting detector CTA for prostate artery embolization pre-procedure planning and intra-procedural guidance.","authors":"Paul Yousif, Forrest Linch, Prabhakar Rajiah, Jeremy D Collins, Christopher P Favazza, Andrea Ferrero, Michael Jundt, Scott Thompson","doi":"10.1186/s42155-025-00567-6","DOIUrl":"10.1186/s42155-025-00567-6","url":null,"abstract":"<p><strong>Background: </strong>Prostate artery embolization (PAE) requires a careful understanding of pelvic arterial anatomy and identifying prostatic artery variants. Pre-procedure CTA and intra-procedural cone beam CT are traditional means of planning and performing PAE, with the latter providing guidance for embolization. Photon counting detector (PCD) CT enables ultra-high spatial resolution (UHR) whole-body imaging. For PAE, we obtain a single UHR PCD CT arterial phase acquisition, which provides both detailed pre-procedure pelvic arterial anatomic information and a dataset for 2D (angiographic) to 3D (CTA) fusion for intra-procedural guidance during PAE using embolization guidance software in the angiography suite.</p><p><strong>Case presentations: </strong>In six patients who underwent technically successful PAE via a left transradial approach, the pre-procedure diagnostic UHR pelvic PCD prostate CTA delineated bilateral prostatic artery origins and course in all cases, as confirmed with conventional angiograms. Further, registration of the UHR PCD CTA for embolization guidance was successful in all cases, augmenting vessel selection. No complication occurred.</p><p><strong>Conclusion: </strong>UHR PCD CTA is a novel imaging technology that can provide detailed prostate arterial anatomic information for pre-procedure PAE planning. Further, this same UHR PCD CTA dataset can be used for intra-procedural embolization guidance using commercially available embolization guidance software.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"55"},"PeriodicalIF":1.2,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long term outcomes following embolisation of bronchial and non-bronchial systemic arteries for the management of haemoptysis - a 20-year experience.","authors":"Shyamal Patel, Lucy Rose Howroyd, Helen Bucknall, Hussain Memon, Robert Morgan, Joo-Young Chun","doi":"10.1186/s42155-025-00551-0","DOIUrl":"10.1186/s42155-025-00551-0","url":null,"abstract":"<p><strong>Background: </strong>Bronchial artery embolisation (BAE) is considered the most effective non-surgical technique for management of moderate-massive haemoptysis. Associated risks include neurological compromise such as stroke and spinal cord ischaemia. We aim to evaluate post-procedural outcomes and complication rates.</p><p><strong>Materials and methods: </strong>A single-centre retrospective observational study was conducted for BAE cases performed between January 2002-June 2022 in a London teaching hospital. Data was collected from electronic medical records and Picture Archiving Communications System (PACS). Primary outcomes were measured, and statistical analysis was performed to identify risk factors for haemoptysis recurrence.</p><p><strong>Results: </strong>One hundred eleven patients underwent 141 procedures with technical success achieved in 87.8% and clinical success in 84.8%. The most common causes of haemoptysis were aspergilloma (24.8%), bronchiectasis (19.1%) and malignancy (11.3%). Haemoptysis recurrence occurred in 65 cases (46%) with 20 patients undergoing repeat embolisation. Aspergillosis, cystic fibrosis, and non-tuberculous pneumonia were identified as risk factors for recurrent haemoptysis (p < 0.005). Pre-procedure MDCTA did not improve technical success. The rate of stroke in the cohort was 6.4% (9 cases), which is more so than quoted in the literature. Four of these patients presented with apical cavitations secondary to infection (aspergilloma or bacterial pneumonia).</p><p><strong>Conclusions: </strong>BAE is an effective endovascular treatment in patients with massive and recurrent haemoptysis. However, there is a well-documented risk of recurrent symptoms and early mortality, particularly in the setting of aspergilloma, cystic fibrosis and non-tuberculous pneumonia. The risk of stroke should not be underestimated. Patients should be counselled appropriately during informed consent prior to embarking on BAE.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"51"},"PeriodicalIF":1.2,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endovascular treatment of a subclavian artery pseudoaneurysm in a patient with a pancoast tumor.","authors":"Samuel J Mouyal, Xavier Guerra, Tom Boeken, Alessandro Di Gaeta, Crina Bordeianu, Manuel Gargiulo, Olivier Pellerin, Marc Sapoval, Marc Al Ahmar","doi":"10.1186/s42155-025-00572-9","DOIUrl":"10.1186/s42155-025-00572-9","url":null,"abstract":"<p><strong>Background: </strong>The authors report herein a rare case of an endovascular management of a giant subclavian artery pseudoaneurysm, revealed by a massive hemoptysis in a patient suffering from a Pancoast tumor.</p><p><strong>Case presentation: </strong>The endovascular procedure consisted of covering the subclavian artery rupture site with a stent graft after occluding the proximal segments of the ipsilateral internal thoracic and vertebral arteries.</p><p><strong>Conclusion: </strong>Subclavian artery rupture was effectively managed using endovascular techniques via radial access.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"52"},"PeriodicalIF":1.2,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Right versus Middle Hepatic Vein access and One-Year TIPS Outcomes.","authors":"Vikrant Khare, Travis Merritt, Natalia Zbib, Linnea Swanson, Maria Masotti, Robert J Fontana, Baljendra Kapoor, Hassan Anbari","doi":"10.1186/s42155-025-00570-x","DOIUrl":"10.1186/s42155-025-00570-x","url":null,"abstract":"<p><strong>Background: </strong>This study evaluates one-year clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) placement using a middle hepatic vein (MHV) versus right hepatic vein (RHV) access. Primary end points were shunt patency and one-year survival. Secondary outcomes included incidence of de novo hepatic encephalopathy (HE) and recurrence of portal hypertension related complications such as ascites, hepatic hydrothorax, and gastrointestinal bleeding. While prior studies have examined portal vein target selection, the clinical relevance of hepatic vein choice remains understudied.</p><p><strong>Methods: </strong>A retrospective chart review of adult patients who underwent TIPS using a Viatorr stent graft between January 2014 and December 2022 was conducted. Patients were included if the procedure used either RHV or the MHV. Intracardiac echocardiography (ICE) was employed to select a direct path from hepatic to portal vein. Shunts were dilated to 8 or 10 mm to achieve a post-procedural portosystemic gradient (PSG) ≤ 12 mmHg or a 50% reduction from baseline. Clinical and imaging data was analyzed to assess outcomes, stratified by hepatic vein of access.</p><p><strong>Results: </strong>One-year survival (84% MHV vs 75% RHV, p = 0.2) and overall one-year patency rates (96% MHV vs 87% RHV, p = 0.5) were similar between the groups. However, MHV access significantly reduced de novo hepatic encephalopathy (30% MHV vs 62% RHV, p = 0.008) and moderate to severe cases (16% MHV vs 42% RHV, p = 0.017). Despite more frequent use of smaller diameter shunts (8 mm: 72% MHV vs 47% of RHV, p < 0.001), MHV access achieved similar post-TIPS portosystemic gradient reductions (Average Pre-TIPS gradient: 17 mmHg MHV & 17 mmHg RHV, p = 0.8; Average Post-TIPS gradient: 8 mmHg MHV & 7.5 mmHg RHV, p = 0.12). Hepatic vein choice did not affect outcomes for ascites, hydrothorax, or gastrointestinal bleeding.</p><p><strong>Conclusion: </strong>MHV and RHV access routes provided similar patency, survival, and TIPS indication outcomes, but MHV access had decreased incidence of hepatic encephalopathy and achieved similar portosystemic gradient reduction while using a smaller diameter shunt. MHV may be a preferred option for patients at higher risk of developing hepatic encephalopathy.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"54"},"PeriodicalIF":1.2,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endovascular treatment of acute limb ischemia for persistent sciatic artery aneurysms: a report of 2 cases.","authors":"Eiji Koyama, Kazuki Tobita, Shun Sawada, Motoaki Kai, Hirokazu Mityashita, Shigeru Saito","doi":"10.1186/s42155-025-00568-5","DOIUrl":"10.1186/s42155-025-00568-5","url":null,"abstract":"<p><strong>Background: </strong>Persistent sciatic artery (PSA) is a rare congenital anomaly associated with various complications, including atherosclerotic changes and aneurysms. These changes can cause limb ischemia, thrombosis, distal embolization of the PSA, rupture of aneurysms, buttock pain, and sciatica due to compression of adjacent tissues. Acute limb ischemia (ALI) is a life-threatening condition. Treatment of ALI includes surgical and endovascular treatments (EVT); EVT includes catheter-directed thrombolysis (CDT) and angioplasty, with thrombolysis being highly effective. In Japan, urokinase is the only insurance-covered thrombolytic agent approved for ALI treatment; however, it is currently unavailable due to manufacturing issues.</p><p><strong>Case presentation: </strong>This case report details the treatment of two women (aged 89 and 82 years) with ALI associated with PSA. In both cases, reperfusion was achieved without CDT and stent grafts were deployed across the PSA aneurysm. The final angiogram showed that the PSA aneurysms had disappeared, and the vessel runoff was maintained. Both patients were successfully discharged from the hospital and experienced no complications over the next 6 months.</p><p><strong>Conclusions: </strong>Two patients with ALI with PSA were treated with EVT without CDT. These cases suggest that EVT without CDT may rescue ALI caused by PSA. Moreover, no standard treatment for sciatic artery remnants has been established. Endovascular treatment with stent grafts may be an option for older patients.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"53"},"PeriodicalIF":1.2,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicenter prospective study evaluating use of EmboCube™ Embolization Gelatin alone or in combination with other embolic agents to control bleeding.","authors":"Olivier Pellerin, Julien Frandon, Glen Schlaphoff, Ross Copping, Carole Déan, Warren Clements","doi":"10.1186/s42155-025-00571-w","DOIUrl":"10.1186/s42155-025-00571-w","url":null,"abstract":"<p><strong>Background: </strong>Embolization is a vital endovascular procedure that can be used to quickly achieve hemostasis in patients experiencing uncontrolled bleeding. This study was conducted to describe real-world outcomes following embolization with a pre-cut absorbable gelatin sponge to control bleeding.</p><p><strong>Methods: </strong>This prospective study was conducted across five hospitals in Australia and France. Inclusion criteria included adults ≥ 18 years who required embolization with EmboCube™ Embolization Gelatin for bleeding. Primary performance and safety endpoints were the proportion of patients that achieved clinical success (i.e., cessation of bleeding post-embolization, the absence of rebleeding at the treated site requiring reintervention within 24 h), and the absence of unanticipated serious adverse device effects within 24 h of the initial embolization, respectively. Secondary endpoints included technical success and serious device- and/or procedure-related adverse events 28 days post-initial embolization.</p><p><strong>Results: </strong>A total of 101 patients (54 males) were enrolled and treated. Sixty-six patients were treated with EmboCube only, 35 patients were treated with an additional embolic to control bleeding. Technical and clinical success rates were 100% and 99%, respectively. No patient experienced an unanticipated serious event related to the embolic. The mean time to hemostasis was 3.4 (± 3.96) minutes. Of the 90 patients that completed 28 days of follow-up, 4 (4.4%) experienced an adverse event (access site hematoma, n = 2; ischemic colitis, n = 1, peritonitis, n = 1).</p><p><strong>Conclusion: </strong>EmboCube is safe and effective for control of acute and sub-acute arterial bleeding, alone or in combination with other embolic agents, when rapid hemostasis is required.</p><p><strong>Trial registration: </strong>Clinicaltrials.gov. Registered 23 March 2022, https://clinicaltrials.gov/study/NCT05307783 .</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"50"},"PeriodicalIF":1.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144192524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is uterine artery embolisation a safe and effective modality to treat submucosal fibroids?","authors":"Rayhab Mashal, Neeral Patel, Bhavna Pitrola, Thomas Sewell, Asmaa Al-Kufaishi, Shabnam Taheri, Mohamad Hamady","doi":"10.1186/s42155-025-00546-x","DOIUrl":"10.1186/s42155-025-00546-x","url":null,"abstract":"<p><strong>Highlights: </strong>• Uterine fibroid embolization (UFE) reduced the median volume of dominant submucosal leiomyomas by 64% and achieved over 90% devascularization in 94.8% of cases.• High patient satisfaction was observed, with 84.5% of patients successfully discharged without needing further intervention.• Severe adverse events were rare, affecting only 3.2% of patients, with pelvic infections being the most significant.• Mild adverse events occurred in 16.8% of patients, including infections requiring antibiotics and persistent vaginal discharge.• A multidisciplinary approach is essential for managing patients with submucosal leiomyomas undergoing UFE to ensure optimal treatment outcomes.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"49"},"PeriodicalIF":1.2,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144163481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controlled expansion stent grafts versus legacy stent grafts for transjugular intrahepatic portosystemic shunt: a single-centre retrospective study on the incidence of hepatic encephalopathy.","authors":"Afonso Fonseca, Rui Ramos, Élia Coimbra, António Caetano, Teresa Neves, Rafaela Pereira, Inês Conde Vasco, Marta Alves, Tiago Bilhim","doi":"10.1186/s42155-025-00557-8","DOIUrl":"10.1186/s42155-025-00557-8","url":null,"abstract":"<p><strong>Purpose: </strong>Assess incidence of hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) in patients treated with 8-10 mm Controlled Expansion diameter VIATORR® (VCX) versus 10 mm diameter first-generation VIATORR® (Legacy) stent-grafts.</p><p><strong>Materials and methods: </strong>Single-centre retrospective study (January 2015 to March 2024), including 132 adult patients with cirrhosis treated with TIPS due to complications of portal hypertension. Outcomes included post-TIPS new onset overt HE, ascites response, re-bleeding, mortality and portal pressure gradient (PPG) before and after TIPS. Comparisons used Chi square and Fisher´s exact test for categorical variables and Student´s t test or Mann-Whitney test for quantitative variables.</p><p><strong>Results: </strong>Indication for TIPS was refractory ascites (n = 82) and variceal bleeding (n = 50). The VCX group (n = 85) and the Legacy group (n = 47) had similar new onset overt HE: 37% (31/85) vs 43% (20/47), respectively (p = 0.31); mortality rates (34% [29/85]) vs 39% [18/47], respectively, p = 0.57) and re-bleeding (17% [6/35] vs 20% [3/15], respectively, p = 1.00). Median PPG reduction after TIPS was 10 mmHg (7 - 13) in the VCX group and 12 mmHg (9 - 15) in the Legacy group (p = 0.02). Subgroup analysis revealed post TIPS overt HE rate of 38% (19/50) in the VCX group vs 53% (17/32) in the Legacy group (p = 0.13), with refractory ascites as an indication. Shunt dysfunction rate was 7% (6/85) in the VCX group (stent thrombosis n = 6, stenosis or malpositioning n = 0) and 0% (0/47) in the Legacy group (p = 0.09).</p><p><strong>Conclusion: </strong>VCX stent grafts induce an immediate lower PPG reduction, which might lead to more stent dysfunctions, but also to a reduction in post-TIPS HE.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"48"},"PeriodicalIF":1.2,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergency endovascular treatment of stroke due to cervical artery dissection - impact of periprocedural GP IIb/IIIa inhibitor use on clinical outcome.","authors":"Abira Sornalingam, Susanne Wegener, Miranda Stattmann, Jil Baumann, Patrick Thurner, Jawid Madjidyar, Hakim Shakir Husain, Miklos Krepuska, Christoph Globas, Andreas R Luft, Zsolt Kulcsar, Tilman Schubert","doi":"10.1186/s42155-025-00564-9","DOIUrl":"10.1186/s42155-025-00564-9","url":null,"abstract":"<p><strong>Background: </strong>Endovascular therapy (EVT) for large intracranial vessel occlusion or symptomatic hypoperfusion due to cervical artery dissection (CeAD) became the standard therapy in recent years. Stenting is frequently required to secure the dissection with subsequent need for GP IIb/IIIa inhibitors. However, a potential concern of antithrombotic therapy in acute stroke is the increased risk of intracerebral hemorrhage. The aim of the study was to assess the impact of the administration of a GP IIb/IIIa inhibitor imaging during endovascular treatment for acute ischemic stroke caused by CeAD on 90-day clinical outcome and intracranial hemorrhage.</p><p><strong>Methods: </strong>This single-center retrospective cohort study enrolled CeAD patients with internal carotid artery (ICA) dissections treated with EVT from January 2015 to August 2022. We analysed the impact of different variables including postinterventional hemorrhage, revascularization success and the use of GP IIb/IIIa Inhibitors (eptifibatide) on 90-day favorable clinical outcome (mRS 0-2). NIHSS Scores were evaluated at different time points in relation to the 90-day clinical outcomes.</p><p><strong>Results: </strong>Forty-nine patients were included in the study. Thrombectomy was performed in all patients. In 33 patients, stenting was performed in addition to thrombectomy. 20 patients (40.8%) received eptifibatide periinterventionally. 31 out of 49 patients (63.3%) had a favorable 90-day clinical outcome (mRS 0-2). Five patients showed radiologically significant hemorrhage. The rate of successful reperfusion (TICI 2b-3) in the favorable 90-day outcome group was significantly higher than in the unfavorable 90-day outcome group.</p><p><strong>Conclusions: </strong>In this study, the use of a GP IIb/IIIa inhibitor use during EVT for stroke caused by CeAD did not affect 90-day clinical outcome nor the incidence of intracranial hemorrhage. Successful reperfusion significantly correlated with favorable clinical outcome.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"47"},"PeriodicalIF":1.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting early clinical success of prostate artery embolization using MRI perfusion in benign prostatic hyperplasia.","authors":"Skander Sammoud, Fabien De Oliviera, Tarek Kammoun, Houssem Loukil, Ghizlane Touimi Ben Jelloun, Sinda Ghabri, Wissem Nabi, Stéphane Droupy, Pascal Gres, Jean-Paul Beregi, Julien Frandon","doi":"10.1186/s42155-025-00562-x","DOIUrl":"10.1186/s42155-025-00562-x","url":null,"abstract":"","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"46"},"PeriodicalIF":1.2,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}